Taysha Gene Therapies, INC. (TSHA) — 8-K Filings

8-K Filings (17)

• Taysha Gene Therapies Files 8-K on Agreements and Financials — Nov 4, 2025 Risk: medium
  Taysha Gene Therapies, Inc. filed an 8-K on November 4, 2025, reporting on the entry into a material definitive agreement, results of operations, and financial
• Taysha Gene Therapies Files 8-K — Oct 16, 2025 Risk: low
  Taysha Gene Therapies, Inc. filed an 8-K on October 16, 2025, reporting other events and financial statements. The filing details the company's principal execut
• Taysha Gene Therapies Files 8-K — Oct 9, 2025 Risk: low
  Taysha Gene Therapies, Inc. filed an 8-K on October 9, 2025, reporting other events and financial statements. The company, incorporated in Delaware with its pri
• Taysha Gene Therapies Files 8-K — Oct 2, 2025 Risk: low
  Taysha Gene Therapies, Inc. filed an 8-K on October 2, 2025, reporting other events and financial statements. The company, incorporated in Delaware, is involved
• Taysha Gene Therapies Files 8-K on Financials — Aug 12, 2025 Risk: low
  Taysha Gene Therapies, Inc. filed an 8-K on August 12, 2025, reporting on its results of operations and financial condition. The filing includes financial state
• Taysha Gene Therapies Files 8-K on Corporate Matters — Jun 3, 2025 Risk: low
  Taysha Gene Therapies, Inc. filed an 8-K on June 3, 2025, reporting on matters submitted to a vote of security holders and financial statements. The filing indi
• Taysha Gene Therapies Files 8-K — May 28, 2025 Risk: low
  Taysha Gene Therapies, Inc. filed an 8-K on May 28, 2025, reporting on various events. The filing includes information related to Regulation FD disclosures, oth
• Taysha Gene Therapies Files 8-K on Financials — May 15, 2025 Risk: low
  Taysha Gene Therapies, Inc. filed an 8-K on May 15, 2025, reporting on its results of operations and financial condition. The filing includes financial statemen
• Taysha Gene Therapies Files 8-K — Feb 26, 2025 Risk: low
  Taysha Gene Therapies, Inc. filed an 8-K on February 26, 2025, reporting on its results of operations and financial condition, as well as financial statements a
• Taysha Gene Therapies Files 8-K — Nov 13, 2024 Risk: low
  Taysha Gene Therapies, Inc. filed an 8-K on November 13, 2024, reporting on its results of operations and financial condition, as well as financial statements a
• Taysha Gene Therapies Files 8-K — Aug 12, 2024 Risk: low
  Taysha Gene Therapies, Inc. filed an 8-K on August 12, 2024, reporting on its results of operations and financial condition, as well as financial statements and
• Astellas to Acquire Taysha Gene Therapies for $1.1 Billion — Jun 26, 2024 Risk: medium
  Taysha Gene Therapies, Inc. announced on June 25, 2024, that it has entered into a definitive agreement to be acquired by a subsidiary of Astellas Pharma Inc. f
• Taysha Gene Therapies Files 8-K — Jun 18, 2024 Risk: low
  Taysha Gene Therapies, Inc. filed an 8-K on June 18, 2024, to report on Regulation FD disclosures and financial statements. The filing does not contain specific
• Taysha Gene Therapies Files 8-K on Shareholder Vote Matters — May 30, 2024 Risk: low
  Taysha Gene Therapies, Inc. filed an 8-K on May 30, 2024, reporting on a submission of matters to a vote of security holders that occurred on May 29, 2024. The
• Taysha Gene Therapies Files 8-K — May 14, 2024 Risk: low
  Taysha Gene Therapies, Inc. filed an 8-K on May 14, 2024, reporting on its results of operations and financial condition, as well as financial statements and ex
• Taysha Gene Therapies Files 8-K — Mar 19, 2024 Risk: low
  Taysha Gene Therapies, Inc. filed an 8-K on March 19, 2024, reporting on its results of operations and financial condition, as well as financial statements and
• Taysha Gene Therapies Files 8-K for Reg FD Disclosure — Jan 10, 2024
  Taysha Gene Therapies, Inc. filed an 8-K on January 10, 2024, to report a Regulation FD Disclosure and Financial Statements and Exhibits. This filing indicates

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX